Skip to ContentSkip to Navigation
About usFaculty of Science and EngineeringResearchGRIPNews and activities

Pharmacoeconomics of cardiovascular disease prevention

16 December 2015

In the thesis of Jana Stevanovic, some of the methodological challenges in simulating and synthesizing pharmacoeconomic evidence in cardiovascular disease (CVD) prevention were assessed and potential solutions to those challenges were proposed. This includes a set of recommendations for enhancing the robustness of pharmacoeconomic analyses that apply CVD risk prediction models. The application of these recommendations was also explored in a simplified model of primary CVD prevention with antihypertensives. Another challenging issue relates to the robustness of evidence on the health-related quality of life (HRQoL) values used in pharmacoeconomic analyses. Here, evidence-synthesis was suggested as a relevant approach to, where appropriate, synthesize HRQoL values in specific CVD disorders as well as to indicate the level of heterogeneity across those values and possibly its sources. As an example, evidence-synthesis of instrument-specific HRQoL values in coronary heart disease and its underlying disease-forms was explored. In this study large heterogeneity within and between the instrument-specific values and inherent uncertainty if applied within pharmacoeconomic analysis, were found.

This thesis also derives pharmacoeconomic evidence on the use of oral anticoagulants (i.e. vitamin K antagonists (VKAs) and novel oral anticoagulants (NOACs) e.g. apixaban, dabigatran) for secondary CVD prevention that may have direct societal relevance and implications in the Dutch setting. Firstly, optimizing the standard anticoagulant care with VKAs was explored. Secondly, the health and economic consequences associated with the use of apixaban for the prevention of stroke in non-valvular atrial fibrillation, and dabigatran for treatment and prevention of venous thromboembolism indicated that both apixaban and dabigatran were favourable alternatives to treatment with VKAs.

In conclusion, several studies in this thesis emphasize that standardizing methodological requirements and recommendations for conducting and reporting pharmacoeconomic studies in CVD prevention including the ones proposed in this thesis may enhance the quality and validity of pharmacoeconomic evidence and reduce possible bias. Furthermore, this thesis provides pharmacoeconomic evidence that NOACs may present a valuable alternative to VKAs for thromboprophylaxis in the Dutch setting.

Dissertation: http://hdl.handle.net/11370/2979abd7-00f8-43ea-baf7-e4e77f0794d8

PhD ceremony: J. Stevanovic, MSc

When: December 22, 2015

Start: 11:00

Promotor: prof. dr. M.J. (Maarten) Postma

Where: Academy building RUG

Faculty: Mathematics and Natural Sciences

Last modified:16 December 2015 11.46 a.m.
printView this page in: Nederlands

More news

  • 11 July 2019

    Major companies’ annual reports too vague about climate impact

    Many major Dutch companies publish extensive information about climate impact in their annual reports. However, very few companies provide concrete, detailed information about their own CO2 emissions, the impact of climate change on their business...

  • 08 July 2019

    UG permanently closes Yantai project

    The University of Groningen (UG) has permanently closed the project aimed at creating a branch campus in Yantai. Discussions were held with China Agricultural University, the city of Yantai and the Province of Shandong.

  • 03 July 2019

    Cheap train tickets boost public transport use but reduce customer satisfaction

    Offers of cheap single train tickets through retailers such as Kruidvat or Etos have a positive impact on the number of kilometres travelled by rail. This impact is much bigger than that of more general TV, newspaper or magazine advertising. However,...